- Home
- DTIL vs CELU Comparison
DTIL vs CELU Comparison
Compare DTIL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- CELU
- Stock Information
- Founded
- DTIL 2006
- CELU 2016
- Country
- DTIL United States
- CELU United States
- Employees
- DTIL N/A
- CELU N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- CELU Health Care
- Exchange
- DTIL Nasdaq
- CELU Nasdaq
- Market Cap
- DTIL 51.6M
- CELU 49.8M
- IPO Year
- DTIL 2019
- CELU N/A
- Fundamental
- Price
- DTIL $4.79
- CELU $1.79
- Analyst Decision
- DTIL Strong Buy
- CELU
- Analyst Count
- DTIL 2
- CELU 0
- Target Price
- DTIL $47.00
- CELU N/A
- AVG Volume (30 Days)
- DTIL 85.2K
- CELU 63.1K
- Earning Date
- DTIL 07-31-2025
- CELU 05-08-2025
- Dividend Yield
- DTIL N/A
- CELU N/A
- EPS Growth
- DTIL N/A
- CELU N/A
- EPS
- DTIL N/A
- CELU N/A
- Revenue
- DTIL $51,141,000.00
- CELU $54,220,000.00
- Revenue This Year
- DTIL N/A
- CELU $23.29
- Revenue Next Year
- DTIL $30.20
- CELU N/A
- P/E Ratio
- DTIL N/A
- CELU N/A
- Revenue Growth
- DTIL N/A
- CELU 138.11
- 52 Week Low
- DTIL $3.61
- CELU $1.00
- 52 Week High
- DTIL $11.09
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- DTIL 44.86
- CELU 44.46
- Support Level
- DTIL $4.20
- CELU $1.78
- Resistance Level
- DTIL $5.29
- CELU $2.10
- Average True Range (ATR)
- DTIL 0.36
- CELU 0.18
- MACD
- DTIL -0.03
- CELU -0.06
- Stochastic Oscillator
- DTIL 36.88
- CELU 10.50
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.